Surrey Heartlands

Joint Formulary & PAD

Spesolimab - Pustular psoriasis

You are here : Home > Formulary Search > Spesolimab - Pustular psoriasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Infusion
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Spesolimab
Indication :
Pustular psoriasis
Group Name :
Keywords :
Brand Names Include :
Spevigo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Spesolimab is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Pustular psoriasis.

  • No records returned.

Committee Recommendations (1)

23 Jan 24 - Not Set

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing .

NICE have not yet provided a publication date but this drug will be considered by the APC within 90 days of NICE publication